AU2017372377B2 - Imidazo [1,5-a] pyrazine derivatives as PI3Kdelta inhibitors - Google Patents

Imidazo [1,5-a] pyrazine derivatives as PI3Kdelta inhibitors Download PDF

Info

Publication number
AU2017372377B2
AU2017372377B2 AU2017372377A AU2017372377A AU2017372377B2 AU 2017372377 B2 AU2017372377 B2 AU 2017372377B2 AU 2017372377 A AU2017372377 A AU 2017372377A AU 2017372377 A AU2017372377 A AU 2017372377A AU 2017372377 B2 AU2017372377 B2 AU 2017372377B2
Authority
AU
Australia
Prior art keywords
compound
6alkyl
heteroaryl
heterocyclyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017372377A
Other languages
English (en)
Other versions
AU2017372377A1 (en
Inventor
Jing Li
Zhiwei Wang
Haibo Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeOne Medicines Ltd
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of AU2017372377A1 publication Critical patent/AU2017372377A1/en
Application granted granted Critical
Publication of AU2017372377B2 publication Critical patent/AU2017372377B2/en
Priority to AU2022203737A priority Critical patent/AU2022203737A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2017372377A 2016-12-07 2017-12-07 Imidazo [1,5-a] pyrazine derivatives as PI3Kdelta inhibitors Ceased AU2017372377B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022203737A AU2022203737A1 (en) 2016-12-07 2022-05-31 Imidazo(1,5-a)pyrazine derivatives as PI3Kdelta inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/108897 2016-12-07
CN2016108897 2016-12-07
PCT/CN2017/114970 WO2018103688A1 (en) 2016-12-07 2017-12-07 IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022203737A Division AU2022203737A1 (en) 2016-12-07 2022-05-31 Imidazo(1,5-a)pyrazine derivatives as PI3Kdelta inhibitors

Publications (2)

Publication Number Publication Date
AU2017372377A1 AU2017372377A1 (en) 2019-07-18
AU2017372377B2 true AU2017372377B2 (en) 2022-03-03

Family

ID=62491736

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017372377A Ceased AU2017372377B2 (en) 2016-12-07 2017-12-07 Imidazo [1,5-a] pyrazine derivatives as PI3Kdelta inhibitors
AU2022203737A Abandoned AU2022203737A1 (en) 2016-12-07 2022-05-31 Imidazo(1,5-a)pyrazine derivatives as PI3Kdelta inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022203737A Abandoned AU2022203737A1 (en) 2016-12-07 2022-05-31 Imidazo(1,5-a)pyrazine derivatives as PI3Kdelta inhibitors

Country Status (16)

Country Link
US (2) US11136323B2 (enExample)
EP (1) EP3551630A4 (enExample)
JP (2) JP7064495B2 (enExample)
KR (1) KR20190091339A (enExample)
CN (2) CN114805366A (enExample)
AU (2) AU2017372377B2 (enExample)
BR (1) BR112019011847A2 (enExample)
CA (1) CA3045959A1 (enExample)
EA (1) EA201991355A1 (enExample)
IL (2) IL266986B (enExample)
MX (1) MX394882B (enExample)
NZ (1) NZ754944A (enExample)
SG (1) SG10201912192RA (enExample)
TW (2) TWI762534B (enExample)
WO (1) WO2018103688A1 (enExample)
ZA (1) ZA201903286B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3551630A4 (en) 2016-12-07 2020-07-15 Beigene, Ltd. IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS
IL272988B (en) 2017-09-08 2022-08-01 Beigene Ltd Imidazo-[1,5-a]pyrazine derivatives as pi3k-delta inhibitors
US20230011916A1 (en) * 2019-11-21 2023-01-12 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors
KR102344185B1 (ko) * 2020-02-26 2021-12-27 계명대학교 산학협력단 신규한 Pim 키나아제 억제제 및 이의 용도
IL308856A (en) * 2021-05-27 2024-01-01 Beigene Switzerland Gmbh SALTS OF A PI3Kdelta INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE
JP2024535799A (ja) * 2021-09-14 2024-10-02 ベイジーン スウィッツァーランド ゲーエムベーハー Btk阻害剤及びpi3キナーゼ阻害剤の組み合わせを使用したがん治療の方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037836A2 (en) * 2003-10-15 2005-04-28 Osi Pharmaceuticals, Inc. Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596185A (en) 2009-04-16 2013-01-25 Ct Nac Investigaciones Oncologicas Cnio Imidazopyrazines for use as kinase inhibitors
RU2013138835A (ru) 2011-02-09 2015-03-20 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения в качестве ингибиторов pi3 киназы
WO2013104610A1 (en) * 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted imidazopyrazines as akt kinase inhibitors
KR102229478B1 (ko) 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
ES2834638T3 (es) * 2013-05-30 2021-06-18 Infinity Pharmaceuticals Inc Tratamiento de cánceres usando moduladores de isoforma de PI3 cinasa
CA2922058A1 (en) * 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
RS62713B1 (sr) 2014-08-11 2022-01-31 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora
EP3551630A4 (en) * 2016-12-07 2020-07-15 Beigene, Ltd. IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS
IL272988B (en) 2017-09-08 2022-08-01 Beigene Ltd Imidazo-[1,5-a]pyrazine derivatives as pi3k-delta inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037836A2 (en) * 2003-10-15 2005-04-28 Osi Pharmaceuticals, Inc. Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cas Registry Number 1025939-56-3; STN Entry Date 6 June 2008 *

Also Published As

Publication number Publication date
TW202233190A (zh) 2022-09-01
EP3551630A1 (en) 2019-10-16
US20190367523A1 (en) 2019-12-05
US11136323B2 (en) 2021-10-05
JP7064495B2 (ja) 2022-05-10
IL266986B (en) 2022-03-01
IL290419A (en) 2022-04-01
US11725012B2 (en) 2023-08-15
AU2017372377A1 (en) 2019-07-18
TW201833113A (zh) 2018-09-16
JP2022090051A (ja) 2022-06-16
EP3551630A4 (en) 2020-07-15
MX2019006612A (es) 2019-08-01
IL290419B2 (en) 2023-02-01
CA3045959A1 (en) 2018-06-14
CN114805366A (zh) 2022-07-29
NZ754944A (en) 2023-02-24
MX394882B (es) 2025-03-24
WO2018103688A1 (en) 2018-06-14
TWI762534B (zh) 2022-05-01
AU2022203737A1 (en) 2022-06-23
CN110267959A (zh) 2019-09-20
CN110267959B (zh) 2022-05-27
ZA201903286B (en) 2021-01-27
SG10201912192RA (en) 2020-02-27
KR20190091339A (ko) 2019-08-05
IL266986A (en) 2019-07-31
US20220098202A1 (en) 2022-03-31
JP2020500909A (ja) 2020-01-16
IL290419B (en) 2022-10-01
EA201991355A1 (ru) 2019-11-29
BR112019011847A2 (pt) 2019-10-29

Similar Documents

Publication Publication Date Title
US11725012B2 (en) Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors
AU2017206820B2 (en) Spiroheptane salicylamides and related compounds as inhibitors of rock
ES2907622T3 (es) Compuestos de heteroarilo como inhibidores de BTK y usos de estos
JP2017527561A (ja) リジン特異的なデメチラーゼ−1の阻害剤
BR112020005934A2 (pt) inibidor de pde9 e uso do mesmo
JP2022551299A (ja) Brd4阻害活性を有する化合物、その調製方法および用途
ES2944658T3 (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de PI3Kdelta
TW202214634A (zh) 雜環化合物及其衍生物
TW202024072A (zh) 作為PI3Kβ抑制劑的1,5-二氮雜萘-4(1H)-酮衍生物
EA040746B1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-а]ПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kδ
HK40088309A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
EA040339B1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-а]ПИРАЗИНА КАК ИНГИБИТОРЫ PI3Kδ
HK40008309B (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
HK40008309A (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
BR102019005173A2 (pt) Composto de pirido de anel aromático de cinco elementos, método de preparação do mesmo e uso do mesmo
HK40029822A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
HK40029822B (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)